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West Nile virus (WNV) is transmitted by mosquitoes
and can cause illness in humans ranging from mild fever to
encephalitis. In 2002, a total of 4,156 WNV cases were
reported in the United States; 329 were in Louisiana. To
estimate the economic impact of the 2002 WNV epidemic
in Louisiana, we collected data from hospitals, a patient
questionnaire, and public offices. Hospital charges were
converted to economic costs by using Medicare cost-to-
charge ratios. The estimated cost of the Louisiana epidem-
ic was $20.1 million from June 2002 to February 2003,
including a $10.9 million cost of illness ($4.4 million medical
and $6.5 million nonmedical costs) and a $9.2 million cost
of public health response. These data indicate a substantial
short-term cost of the WNV disease epidemic in Louisiana.
W
est Nile virus (WNV) is transmitted by mosquitoes
and can cause illnesses ranging from simple fevers
to encephalitis (1). The presence of this virus in the
Western Hemisphere was first recognized in New York
City in 1999 (2). In 2002, an epidemic of WNV illness
focused in the midwestern United States resulted in 4,156
reported cases; 2,942 cases had central nervous system
(CNS) illness (meningitis, encephalitis, or acute flaccid
paralysis), and 284 died (3). A total of 329 persons with
WNV disease were reported in Louisiana, with illness
onsets from June to November. Among these, 204 had ill-
nesses involving the CNS; 24 died (Louisiana Office of
Public Health, unpub. data).
Economic data about epidemics are essential for esti-
mating the costs and benefits of strengthening and main-
taining prevention and control programs, improving
existing surveillance systems, and introducing other pro-
posed interventions, such as vaccines. Although some esti-
mates exist of the economic impact imposed by diseases
transmitted by mosquitoes (4–9), to our knowledge, no
previous studies have assessed the costs of a WNV disease
epidemic. We estimated the magnitude of the short-term
economic costs of the 2002 WNV epidemic in Louisiana.
Economic Model, Data, and Methods
We calculated the costs of the WNV epidemic as the
sum of 1) medical costs (inpatient and outpatient); 2) non-
medical costs, such as productivity losses caused by illness
and premature death, costs of transportation for a patient to
visit a healthcare provider, and childcare expenses; and
3) costs incurred by public health and other government
agencies for epidemic control. Data were gathered from
hospitals in Louisiana that had WNV patients; a phone sur-
vey of WNV patients (all adult patients with nonfatal cases
for whom phone numbers were available from the
Louisiana Office of Public Health were included in the sur-
vey); and public offices, including the Louisiana Office of
Public Health, state and local governments, and the
Louisiana Office of Emergency Preparedness. Because
information could not be gathered for all hospitalized
patients and the patient questionnaire could not be admin-
istered to all reported patients, we extrapolated cost data,
assuming that the costs for those with information were
representative of those without information (the extrapola-
tion method is described in Appendix 1).
We took a societal perspective, evaluating all costs
regardless of who bore them. The costs were estimated
from June 2002, when the epidemic was first recognized,
until the last date we administered the phone survey,
February 27, 2003, some 3 months after the onset of illness
of the last reported patient. Intangible costs, attributable to
factors such as pain and suffering, were not included.
Medical Costs
Inpatient Costs for Acute Care and Rehabilitation
In fall 2002 we requested information from Louisiana
hospitals on the length of hospital stay and inpatient and
outpatient treatment charges, including therapies at inpa-
tient rehabilitation facilities for patients who met the case
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(http://www.cdc.gov/epo/dphsi/casedef/encephalitiscur-
rent.htm). To ensure patient anonymity, patient informa-
tion from hospitals was given to the study investigators
unlinked to personal identifiers, and only the 16 hospitals
with more than three adult patients (>18 years old) were
queried. Adults constituted 94% of reported WNV case-
patients in Louisiana.
Twelve hospitals submitted information from
159 patients, including inpatient treatment charges for
119 patients and hospital outpatient treatment charges for
50 patients. Ten of these 50 patients had both inpatient and
outpatient treatment charges. Patient charges included
65 inpatient treatment or service types, which we grouped
for the analysis into eight categories (Table 1). For exam-
ple, we pooled hospital charges originally listed as “phar-
macy,” “drugs,” “injection,” “medical/surgical supplies,”
“IV solutions,” “IV therapy,” and “prosthetic devices” into
the category “pharmacy/medical supplies.”
Because charges for healthcare products or services may
not represent their true economic cost (Appendix 2), i.e.,
the opportunity cost of a resource used for producing goods,
services, or both (10,11), we converted hospital charges to
economic costs by using Medicare cost-to-charge conver-
sion rates (12). Charges made by healthcare providers are
generally higher than the cost of resources used
(Appendix 2). For Louisiana, the cost-to-charge ratios were
0.410 for urban areas and 0.488 for rural areas (e.g., in
urban areas, a $1 charge has an estimated $0.41 economic
cost). Two of 12 participating hospitals were in rural areas.
Of 119 patients for whom inpatient treatment charges
were available, 7 incurred costs for inpatient rehabilitation
treatment. These inpatient rehabilitation treatment charges
were provided by acute-care hospital–based rehabilitation
centers. Charges were converted into costs as described
above. The costs of treatment for the seven patients were
then extrapolated to estimate the total costs for all CNS
patients requiring rehabilitation by using the methods
described earlier.
Outpatient Costs, Medication, 
and Durable Medical Equipment
Information for estimating medical doctor visit costs,
outpatient rehabilitation treatment costs, and nonmedical
costs, including productivity losses, was gathered by inter-
views using a questionnaire administered by telephone
from December 7, 2002, until February 27, 2003 (ques-
tionnaire provided in Online Appendix [www.cdc.
gov/ncidod/EID/vol10no10/03-0925_app.htm]). Phone
numbers for 236 adult patients with nonfatal WNV cases
were available from the Louisiana Office of Public Health.
Of these 236 persons, 139 were interviewed, 46 did not
answer the phone (at least three calls were made at differ-
ent times of day), 4 were deceased, 2 denied WNV illness,
and 16 refused to participate. Twenty-nine of the phone
numbers were listed incorrectly or were disconnected.
We collected information about general practice, spe-
cialist, and outpatient rehabilitation treatment visits
through the patient questionnaire. We estimated the costs
for these visits by using a private health insurance claims
database (Marketscan database 1999, The MEDSTAT
Group, Inc., Ann Arbor, MI). This database is compiled
from health insurance claims submitted to 40 self-insured
employers and represents over 5 million covered lives
across the United States. Average payments made to
healthcare providers in the United States in 1999 were cal-
culated for each service. Costs of specialist visits were
estimated on the basis of relative prices compared to the
national average payments for general practitioners.
Relative prices for medical specialists and hospital-based
specialists were 1.18 and 3.65 times those of primary care
physicians, respectively (13). We used the Consumer Price
Indices (CPI) for medical care to adjust the 1999 payments
for inflation through the year 2002 (14).
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available for 50 patients. Although outpatient treatment
costs for hospitalized and nonhospitalized patients might
be different, the available data could not be separated and
thus the outpatient costs that were estimated based on the
combined data for hospitalized and nonhospitalized
patients were extrapolated to all reported WNV cases.
Although 60% of the questionnaire respondents indi-
cated outpatient medication expenses, these respondents
could not accurately recall the names and amounts of med-
ications taken. Therefore, we did not include outpatient
medication costs in the total cost of the outbreak.
The questionnaire was used to gather information about
durable medical equipment use. Equipment costs were
estimated on the basis of the 1999 MedStat Marketscan
database data (Appendix 3) and adjusted to 2002 dollars by
using a CPI medical care component. Assuming that the
patients for whom durable equipment data were available
(139 questionnaire respondents) were representative of all
204 CNS patients, we extrapolated the costs to all CNS
patients requiring durable equipment.
Nonmedical Costs
Productivity Losses Attributable to Illness and Death
We used the human-capital method to estimate produc-
tivity losses attributable to illness and death (10). The pro-
ductivity losses are measured as income forgone because
of illness or premature death. These losses are also referred
to as mortality cost. Information about workdays missed
by patients or caregivers was obtained through the patient
questionnaire. Of 139 respondents, 65 were employed
before becoming infected with WNV. Respondents provid-
ed information about their earnings; income data were
missing for 12 of 65 patients and for 15 of 36 caregivers
who missed work to care for a patient. For these cases we
used Bureau of Labor Statistics 2001 Louisiana state occu-
pational employment and wage estimates (15), converted
to 2002 dollars using the ratio of 2002 hourly wages to
2001 hourly wages (16). Ten of these 65 patients reported
stopping work entirely because of WNV illness. Because
the dates when each stopped working were not available
and when each could resume work was unknown, we esti-
mated their productivity losses from the second week of
August (about half of Louisiana cases occurred before this
date) until the last patient interview on February 27, 2003.
Respondents provided information on their earnings
before they stopped working. We estimated their produc-
tivity losses with the methods described.
The Louisiana Office of Public Health provided demo-
graphic information about patients who died. For persons
<75 years of age, mortality costs were estimated as the
present value of labor market earnings and household pro-
duction based on productivity loss tables (17). Because the
tables presented the current values of productivity losses at
5-year intervals, we interpolated the present values for
consecutive ages within that 5-year interval and chose the
values corresponding to deceased patients.
For persons 76–85 years of age, we used productivity
loss tables on the annual weighted average earnings (1990
dollars adjusted to 2002 dollars [16]) by age group for
labor-force and nonlabor-force persons(18). We estimated
the expected lifespan for each age group using life tables
for the total U.S. population (19) (Appendix 4). Then we
added the annual earnings by age throughout the expected
lifespan of the person, while making adjustments for a 3%
discount rate (defined in Appendix 2) to calculate the pres-
ent value of the person’s earnings during future years of his
or her lifespan (3% discount rate is recommended by the
U.S. Public Health Service Panel on Cost-Effectiveness in
Health and Medicine [20]) and a 1% annual productivity
increase (1% is the usual assumption for long-term growth
in labor productivity [17]).
Nursing Home, Transportation, 
and Miscellaneous Costs
Information about nursing home admissions and length
of stay because of WNV illness was obtained through the
patient questionnaire. We used the average daily cost for
nursing homes in Louisiana from General Electric’s long-
term care insurance data (21).
The questionnaire obtained information on the frequen-
cy of doctors’ visits and the distance that patients had to
travel to see a physician. Transportation costs were esti-
mated by using the U.S. federal government reimburse-
ment rate of 36.5 cents per mile (22). Information about
payments made for home health aides and miscellaneous
services, such as cleaning, garden work, or babysitting,
was obtained through the questionnaire.
Costs of Public Agencies
The Louisiana Office of Public Health incurred costs
for laboratory support (human serum processing, diagnos-
tic tests), epidemiologic aid (assessment of vector mosqui-
to populations, active surveillance), administrative and
clerical activities, and communication services.
Information on these expenses was provided by the
Louisiana Office of Public Health central office. State and
local governments incurred costs for emergency vector
control. Only expenditures resulting from the 2002 WNV
epidemic in Louisiana that were above and beyond normal
operating expenses were attributed to the WNV epidemic.
The core document used to estimate mosquito control
program costs in Louisiana was the Louisiana Office of
Emergency Preparedness summary of state reimbursement
requests by 93 entities, such as mosquito abatement pro-
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spond to counties, and police juries to county boards of
commissioners or similar local governing bodies in other
states), and city governments. Expenses eligible for state
reimbursement were for overtime labor, rented equipment,
and materials exceeding normal budget expenses from June
1 to mid-August 2002. This amount, however, did not cover
“payment-in-kind” activities, such as unpaid overtime, the
transfer of employees from one activity to another, and
replacement or repair of existing equipment extensively
used during the epidemic. Many mosquito control units
continued WNV control activities from mid-August until
November. After November, we gathered from 18 mosqui-
to control units and local government offices an updated
estimate of all expenses incurred in 2002 attributable to the
WNV epidemic. The ratio of reimbursement requests to
total estimated expenses for these 18 entities was 1:1.7. The
total requested state reimbursement amount for the 93 enti-
ties was multiplied by this ratio to get an estimate of the
total expenses for mosquito control attributable to the
WNV epidemic in Louisiana. No data were available to
allow us to sample the entities by their size or scope of
operation. Therefore, the mosquito control programs and
local governments that responded to our inquiries may not
have been representative of all the entities.
Results
The source of data and the estimated number of cases
that incurred costs in each cost category are presented in
Table 2. A summary of all estimated costs for the 2002
Louisiana WNVepidemic is presented in Table 3. The total
estimated cost of the WNV epidemic in Louisiana in 2002
was $20.14 million.
Medical Costs
Acute-Care Inpatient Costs and Inpatient
Rehabilitation Costs
We received information about acute-care hospital
inpatient charges for 119 patients. Total charges for these
119 patients were $5.1 million, from which we estimated
an economic cost of $2.1 million (the median cost per
patient was $8,274, with a range of $623–$164,688)
(Table 1). The economic costs for 71 (60%) patients were
<$10,000 (Figure). If we assume that the total number of
hospitalized patients with WNV in Louisiana was equal to
the number of CNS illness cases, the estimated total costs
of inpatient hospitalization were $3.6 million for the 204
CNS illness patients.
The median hospital stay was 8 days, with a median of
7 days for intensive care (Table 4). The daily median costs
of stay were $160 for a standard room (range $98–$392),
$537 for the intensive care unit (range $220–$1226), and
$249 for the intermediate, post–intensive care unit (range
$161–$314).
Nineteen (14%) of 139 survey respondents received
inpatient treatment at a rehabilitation facility. Hospital
charges were available for seven patients; the total cost for
inpatient rehabilitation treatment for those seven patients
was $96,556. Using the methods described in Appendix 1,
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Louisiana received inpatient rehabilitation treatment at a
total cost of $386,000.
Costs of Outpatient Hospital Treatment and
Physician Visits
Of 159 patients for whom hospital charges were avail-
able, 50 (32%) received outpatient hospital treatment at a
total cost of $14,539. Using these numbers, we estimated
that 103 of 329 persons reported to the Louisiana Office of
Public Health received outpatient hospital treatment, at an
estimated cost of $30,000. The estimated total cost of vis-
its to see a primary care doctor, specialist, or both for 139
patients who responded to the survey was $54,572; extrap-
olating this figure to the 329 reported WNV cases yielded
an estimated cost of $129,000.
Costs of Outpatient Rehabilitation Therapies and
Durable Medical Equipment
Thirty-one (22%) of 139 respondents reported receiv-
ing outpatient physical therapy, with an estimated cost of
$110,184. Ten of 139 patients reported receiving occupa-
tional therapy, with a total estimated cost of $35,207. Two
patients received speech therapy, at a total estimated cost
of $1,025. The total estimated cost for outpatient rehabili-
tation therapy for these 139 survey respondents was
$146,417; extrapolating this figure to 204 CNS case-
patients in Louisiana yielded an estimated cost of
$215,000. The cost of durable medical equipment (36 of
139 respondents used medical durable equipment such as
a wheelchair, walker, cane, breathing treatment machine,
treadmill, and hospital bed) extrapolated to the 204 CNS
case-patients was an estimated $31,000.
Nonmedical Costs
Productivity Losses from Illness and Death
For 53 patients who missed work but did not stop work-
ing entirely, the estimated productivity losses were
$443,000 (the average number of days missed was 50, and
the median number of days missed was 37, with a range of
1 to 212 days). Extrapolating this figure to 204 CNS
patients, we estimated that 78 missed work, at a total pro-
ductivity loss of $652,000. For the 10 patients who stopped
working entirely, the estimated productivity losses were
$157,950. Based on these data, we estimated that 15 of 204
CNS patients stopped working entirely, at a total cost of
$237,000 (Appendix 1). Thirty-six of 139 respondents
indicated that someone missed work to take care of them;
the resulting productivity loss totaled $82,669 dollars. The
extrapolated cost for caregivers for the 204 CNS patients
was $122,000. The total extrapolated illness cost attributa-
ble to WNV infection was $1.01 million.
Twenty-four deaths were attributed to WNV illness in
Louisiana in 2002. The median age of deceased patients
was 78 (range 27–94). The total estimated mortality cost
for these 24 persons was $5.4 million, which was >50% of
the illness-associated costs and >25% of the total costs of
the epidemic.
Nursing Home, Transportation, 
and Miscellaneous Costs
Five (4%) of 139 patients 45–86 years of age were
reported to have spent 21–170 days in a nursing home
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these patients remained in a nursing home at the time of
their interviews in December 2002 and February 2003.
The estimated total payment for nursing home care for the
five patients was $36,956; the total estimated nursing
home costs for Louisiana CNS patients were $54,000.
The estimated transportation cost for 139 respondents
was $8,354. If one assumes that the transportation costs
for the 139 respondents were representative of costs for
those who did not participate in our survey, the estimated
total cost of transportation for the 329 WNV cases was
$20,000.
Twenty survey respondents reported having used home
health aides or other services, such as babysitting, house
cleaning, or yard work, at a reported total cost of $29,225.
When this figure is extrapolated to the 329 WNV cases in
Louisiana, miscellaneous expenses were at least $69,000.
Costs of Public Agencies
Mosquito Surveillance and Abatement
From June 1 to mid-August, 2002, a total of 93 public
offices requested $4,879,070 as state reimbursement from
the Louisiana Office of Emergency Preparedness.
Eighteen mosquito control units and local government
offices reported their estimated total expenses. Using the
ratio of the sums of the requested reimbursement amounts
to the total reported expenses of $1:$1.7, we estimated that
the cost of mosquito surveillance and abatement programs
for these 93 entities was $8.3 million.
Public Health Office Costs
From June to November 2002, the central state public
health office incurred an estimated $886,000 in expenses
because of WNV. From this total amount, basic operating
expenses cost $586,000, contracts such as for veterinary
diagnostic and entomologic services cost $166,000, and
laboratory expenses cost $134,000.
Discussion
We estimated that the costs from June 2002 to February
2003 attributable to the 2002 WNV epidemic in Louisiana
were $20.1 million (Table 3). This figure is likely an
underestimate since some of the costs associated with ill-
ness or public health response were not available, such as
costs for outpatient medication and costs incurred by per-
sons with WNV infections who were not identified or
reported to Louisiana Office of Public Health. Long-term
costs of WNV illness sequelae were not evaluated.
Although the costs of medical care, wages, and cost of
living vary by region, we assumed that the Louisiana costs
were representative of those elsewhere in order to roughly
estimate the magnitude of the WNV epidemic nationwide.
Extrapolating to the 4,156 cases (2,942 CNS cases) report-
ed nationwide, the short-term costs of inpatient treatment
would be $57.5 million, outpatient treatment costs would
be $5.6 million, and nonmedical costs would be $76.7 mil-
lion, for a sum of $139.8 million. This figure does not
include mosquito abatement and prevention costs (mosqui-
to control capabilities vary tremendously from state to
state), which accounted for approximately half of the costs
in Louisiana.
To our knowledge, only a study of the 1966 St. Louis
encephalitis virus epidemic in Dallas, Texas (172 cases, 20
deaths), estimated the cost of a mosquitoborne disease epi-
demic in the United States (4). The total costs of that epi-
demic were an estimated $796,500 in 1966 dollars.
Adjusting each cost component by the appropriate CPI
(using CPI for all items or for medical care), the total epi-
demic cost was $5.4 million in 2002 dollars, from which
the largest share was for epidemic control expenditures
($348,500 in 1966 dollars [$1.9 million in 2002 dollars]).
The time frame of our study was from June 2002, when
the epidemic was first recognized, until the last date we
administered the survey, February 2003, some 3 months
after the onset of illness of the last reported case-patient.
Several patients, however, likely incurred further costs
beyond the date of their interview. Seventy-three (53%) of
139 survey respondents indicated that they expected to get
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Figure. Number of hospitalized patients (N = 119) with West Nile
virus infection, by cost of inpatient treatment; Louisiana, 2002. further treatment because of health problems caused by
WNV. When, or if, those who stopped working will be able
to resume work is also unknown. Another limitation of our
study was the possible bias in the estimations that were
based on the information gathered by the patient survey.
We did not have the information to determine whether dif-
ferences existed between the nonrespondent and respon-
dent groups.
Although the future incidence of WNV disease cannot
be predicted, WNV incidence will likely remain substan-
tially greater than the total incidences of arbovirus infec-
tions previously known to be endemic to the United States
(23). These Louisiana data suggest that even short-term
costs attributable to WNV epidemics are substantial.
The costs associated with WNV epidemics such as
those documented here can be used to evaluate the eco-
nomics of WNV prevention and control programs. To fully
evaluate the economics of prevention programs, epidemio-
logic and mosquito control data related to program effec-
tiveness are necessary. 
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Appendix 1. Extrapolation Methods
If we assume that the case-patients for whom data were avail-
able were representative of case-patients for whom data were not
available, to estimate the total cost of all applicable cases, Ctotal,
first we estimated the total number of cases who would have
incurred costs in that particular cost category, Ncost-total.
Ncost-available indicates the number of case-patients who
incurred costs in that particular category out of all case-patients
for whom data were available, Navailable, which also includes case-
patients with zero costs. Ntotal is the number of all case-patients
who potentially could have incurred costs in that cost category,
for example, the number of total WNV case-patients in
Louisiana, or the number of total central nervous system case-
patients infected with WNV in Louisiana. The total cost for a
given cost category would be:
where Cavailable is the cost for available cases.
All extrapolated estimates presented in the paper are rounded
to their nearest $1,000.
Appendix 2. Explanation of Economic 
Terms for Noneconomists
Economic (True) Cost and Cost-to-Charge Ratios
Economic (true) cost means opportunity cost of a resource.
Economists are usually interested in societal costs of health pro-
grams—the value of benefits that would have been derived if the
resources had been allocated to their next best use, i.e., the oppor-
tunity cost of resources. In perfect markets (explanation of costs
in perfect markets follows the definition of cost-to-charge ratios),
the market prices of resources reflect their opportunity costs.
Because of healthcare market imperfections (explained below),
charges made by healthcare providers do not usually reflect
opportunity cost and are generally higher than the cost of
resources used (explanation for the reasons of charges being
higher than costs in health care is provided in this appendix under
subtitle Asymmetric Information). Large insurance companies
and the government (Medicare/Medicaid) reimburse hospitals
and physicians at a much lower rate than the charges made by the
healthcare provider. These reimbursements are closer to the actu-
al costs of the resources used than the charges made by the
healthcare provider. 
The common method for estimating the true economic cost of
medical services is adjusting the charges through the use of “cost-
to-charge ratios.” Cost-to-charge ratios are coefficients devel-
oped by expert panels to convert charges for medical services to
their true economic costs. They represent an average estimate of
true costs. The Federal Register publishes state by state Medicare
cost-to-charge ratios every year. The ratios are different for urban
and rural areas. 
Costs in Perfect Markets 
Obtaining the opportunity cost of a resource is difficult. In
perfect markets, the market prices of resources reflect their
opportunity costs. Therefore, to determine opportunity costs, we
have to collect market prices for goods traded in perfect markets.
Perfect market conditions exist when 1) numerous buyers and
sellers can enter and withdraw from the market at no cost, 2) all
buyers are identical, 3) all buyers possess the same relevant infor-
mation, and 4) goods and services traded are the same. In reality,
one or many conditions of perfect markets are violated in most
markets. Economists call them imperfect markets. Various meth-
ods are used to estimate the costs of resources when conditions
for a perfect market are violated or the resources are not traded in
the marketplace. Healthcare markets do not meet the conditions
for perfect markets for a number of reasons, including those dis-
cussed in the following sections. 
Asymmetric Information 
Consumers in healthcare markets generally have little infor-
mation about the treatments medical professionals offer them.
They are at a disadvantage to make fully informed choices.
Economists refer to such a difference in access to information
between market participants as asymmetric information.
Asymmetric information allows the sellers to charge prices for
medical services that are higher than opportunity costs. 
Market Power 
The size and limited number of health insurance companies—
the important participants in healthcare markets who “buy” care
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cosfrom providers—gives them considerable market power to influ-
ence the prices of goods and services sold in that market. Health
insurance companies representing large numbers of subscribers
use their weight to negotiate discounts from hospitals and doctors
(the “sellers”). Therefore, the prices paid to providers vary with
the insurance status of patients and do not correspond to opportu-
nity costs. For more details on economic costs and cost-to-charge
ratio method, see Haddix et al. (1) or Meltzer (2). 
Discount Rate
Discounting is an economic notion that, even in a world of
zero inflation, a dollar today would be of higher value to a person
than a dollar in the future. Adollar today can be used to purchase
a good or service now instead of making the purchase later. This
concept is referred to as time preference. The premium placed on
benefits today versus the future is reflected in the rate at which a
person is willing to exchange present for future costs and bene-
fits. This quantitative measure of time preference is called the
discount rate. When the costs or benefits under the study contin-
ue in the future, in order to make them comparable in terms of the
time dimension economists calculate the present value of these
costs or benefits by using discount rates. The U.S. Public Health
Service Panel on Cost-Effectiveness in Health and Medicine rec-
ommends a 3% discount rate for economic studies in health (3).
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Appendix 3. Estimating Costs of Durable
Equipment
Costs vary among the types of similar durable equipment. For
example, costs for different types of wheelchairs vary consider-
ably. Because the particular type of equipment each patient used
could not be accurately ascertained, we estimated the expected
cost of that equipment on the basis of data available from the
Marketscan database, which provided average national payments
for each type of durable equipment. Let Ni be the number of pay-
ments reported to Marketscan for the ith type of the equipment,
where i=1,2, … n. N is the total number of payments reported to
Marketscan for all types of that durable equipment:
Ciis the mean payment for the ithtype of equipment. For certain
equipment, such as wheelchair, Ci might represent an average
payment for rental of that equipment. Since we do not know the
type of equipment the patient bought or rented, we view the rel-
ative frequency
as the probability of a patient purchasing that particular type of
equipment. We estimated the expected cost of the given durable
equipment as:
Appendix 4. Estimating Expected Life 
Years for a Person
The life table of the total U.S. population for the year 2000
provided numbers of survivors, by 1-year increments, from birth
to a given age, starting with a cohort of 100,000 people (1). At
each age, the expected life years for the surviving cohort was also
provided. The expected life years for a person in our study, ELYi,
was estimated as the product of the person’s survival rate and the
expected life years for the cohort, ELYcohort, where the survival
rate for a person is equal to the ratio of the number of survivors
until the expected age for the cohort, Nsurvivors, to the number of
persons in the cohort at a given age, Nindividuals:
The estimated expected life years for a person 76 or 77 years
of age were 5 years. For persons 78–81 years of age, the estimat-
ed individual life years were 4. For persons 82–84 years, the
expected life years were 3. We assumed that for persons >85
years, the productivity losses were 0; therefore, the expected life
years for persons >85 were not relevant in our application.
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